Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The mechanism of action of hydroxyurea (HU) in decreasing the frequency of pain crisis in sickle cell disease (SCD) has not been fully elucidated. In vitro and in vivo studies suggest that nitric oxide (NO), a potent vasodilator, may partly be responsible for the beneficial effect of HU. This study was designed to determine the effect of oral administration of HU on plasma levels of NO metabolites (NO(x) ) in sickle cell patients (SCP). The results indicate that during steady-state plasma levels of NO(x) were significantly higher in HU-treated patients compared to non HU-treated patients or normal controls (p <.05). In five inpatients in mild pain plasma levels of NO(x) increased significantly after 2 h of HU administration (p <.05); however, in three inpatients in persistent pain with significantly lower baseline NO(x) there was a minimal NO(x) response to HU at 2 h (p <.01). These observations indicate that HU administration is associated with the production of NO in some SCP, but that further study of the pharmacodynamics of this effect is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Cited by
Zhang, D., Xu, C., Manwani, D., & Frenette, P. S. (2016) · Blood · doi:10.1182/blood-2015-09-618538 · Cited by 413
Čokić, V. P., Smith, R. D., Beleslin‐Čokić, B. B., Njoroge, J. M., Miller, J. L., Gladwin, M. T., & Schechter, A. N. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16672 · Cited by 375
Arginine Therapy: A New Treatment for Pulmonary Hypertension in Sickle Cell Disease?
Morris, C. R., Morris, S. M., Hagar, W., van Warmerdam, J., Claster, S., Kepka-Lenhart, D., Machado, L., Kuypers, F. A., & Vichinsky, E. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-967oc · Cited by 329
Guasch, A., Navarrete, J., Nass, K., & Zayas, C. F. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2002010084 · Cited by 241
The Perfusion Paradox and Vascular Instability in Sickle Cell Disease
NATH, K. A., KATUSIC, Z. S., & GLADWIN, M. T. (2004) · Microcirculation · doi:10.1080/10739680490278592 · Cited by 102
Metadata
- Authors
- Nahavandi, M., Wyche, M. Q., Perlin, E., Tavakkoli, F., & Castro, O.
- Venue
- Hematology
- Publisher
- Informa UK Limited
- Published
- 2000-01
- Volume
- 5
- Issue
- 4
- Pages
- 335-339
- ISSN
- 1024-5332 (ISSN-L)
- 1607-8454
- OpenAlex
- W2460895384
- Cited by
- 52
- References
- 1
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea. https://app.cochat.ai/papers/10.1080/10245332.2000.11746528
- The paper
- Nahavandi, M., Wyche, M. Q., Perlin, E., Tavakkoli, F., & Castro, O. (2000). Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea. Hematology. https://doi.org/10.1080/10245332.2000.11746528
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.